Public Policy
Advancing Understanding at the Intersection of Evidence and Policy
The Center for Innovation & Value Research advances a more transparent, equitable, and patient-centered approach to healthcare policy. Through rigorous research, multi-stakeholder convenings, and clear communication of complex evidence, we help shape understanding of how value can guide better decisions across the healthcare system.
Our policy work focuses on translating data and research into insight, helping policymakers, payers, researchers, and patient communities explore how patient-centered value assessment and value-based frameworks can improve access, affordability, and outcomes. We bring together diverse perspectives to identify common ground and promote approaches that balance affordability with sustained innovation and equity.
Each of our policy initiatives reflects a commitment to evidence, collaboration, and patient-centricity. From examining the Inflation Reduction Act’s Drug Price Negotiation Program to exploring international reference pricing and the evolution of value assessment, the Center provides the research and shared learning needed to inform thoughtful policy design.
Our Focus Areas
- Advancing patient-centered approaches to value assessment and policy development
- Promoting transparency and methodological rigor in evidence and pricing analyses
- Integrating patient perspectives and real-world data to strengthen health equity
- Providing educational resources that clarify the impact of emerging policies
Our Public Policy Council serves as a strategic advisory body that helps the Center translate pateient-centered value research into actionable public policy insights. The Council provides expert guidance on policy relevance, emerging issues, and opportunities to inform healthcare decision-making.
Explore Our Policy Work
Read our latest policy statements and comment letters to learn how the Center’s research and convenings are shaping a more informed, patient-centered, and value-driven healthcare system.
- October 30, 2025 || Response to the Draft Report of the Health Economics Methods Advisory (HEMA): "Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies" || View
- July 31, 2025 || Statement from the Center for Innovation & Value Research on President Trump's July 31st Ultimatum on Most Favored Nation || View
- June 26, 2025 || The Center Comments on the CMS Draft Guidance for the Medicare DPNP || View
- May 13, 2025 || The Center Responds to MFN Executive Order || View
- June 28, 2024 || The Center (formerly IVI) Provides Comments on CMS' Drug Price Negotiation Program || View
- September 28, 2023 || IVI Responds to Final ICER Value Assessment Framework || View
- August 29, 2023 || IVI Responds to CMS' Announcement of Prescription Drugs Under the Inflation Reduction Act || View
- July 26, 2023 || Maximizing Value and Equity: CMS Must Prioritize Value, Equity, and Patient Engagement in Drug Price Negotiation Program Implementation || View
- July 11, 2023 || IVI Submits Comments on FDA's Patient-Focused Drug Development Program || View
- June 30, 2023 || IVI Responds to the ICER 2023 Value Assessment Framework || View
- May 5, 2023 || IVI Makes Patient-Centered Recommendations to CMS for Medicare DPNP || View
- March 19, 2023 || IVI Statement in Response to ICER's Health Equity Report || View
PUBLIC POLICY COUNCIL
Nitzan Arad, LLM
Duke-Margolis Institute for Health Policy
Greg Daniel, PhD, MPH
Eli Lilly & Company
Lisa Feng, DrPH (Board Liaison)
Alexion, AstraZeneca Rare Disease
Christina Hochul, JD, LLM
Astellas
Jennifer Houlihan, MSP
Advocate Health
Fauzea Hussain, MPH
McKesson
Anna Hyde, MA
Arthritis Foundation
Imomotimi (Timmy) Imomotebegha, MSc, MS
The George Washington University
Richie Kahn, MPH
Canary Advisors
Silas Martin
J&J Innovative Medicine
Claire Sachs, MA
TPAC Consulting
Daneen Sekoni
Cancer Support Community